Markets

The target indication for our lead compound ATR-002, is represented by “Influenza in high-risk patients”. Annual vaccination continues to be the prime prophylaxis against seasonal influenza outbreaks: According to the WHO, only a minority of the population is effectively protected!

Atriva Markets

Some facts:

  • Globally, Influenza occurs in adults with an annual incidence rate estimated at 5%–10%. Infection can result in hospitalization and death mainly among high-risk groups (the very young, elderly or chronically-ill patients)
  • High-risk conditions include people with asthma, heart disease, chronic obstructive pulmonary disease, diabetes, or cancers other than skin cancer. Furthermore, toddlers, infants and children, pregnant women, elderly patients, healthcare professionals and occupancy workers belong to the high-risk population segment.
  • Worldwide, annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, responsible for 250 000 to 500 000 deaths
  • Median vaccination coverage remains in the range of approx. 40% both in the US and major EU countries in adults except for UK and NL. Vaccine coverage did not increase over recent years and the target-coverage of 75% for 2020 is out of reach both in the USA and most European countries
  • Vaccine coverage in high-risk/chronic conditions with vaccination recommendation like cardiovascular and respiratory diseases, as well as diabetes remains below 50% in adult patients aged 18 to 64 years
  • Vaccine effectiveness for recent strains like H3N2 has been very poor during last years, ranging from 15% to 42% in Western countries. Furthermore, vaccine efficacy decreases significantly with patient age. In the flu season 2016/17 particular low figures have been reported for elderly above 60 years

 

Atriva Markets

Excess consultations were as high as 6 Mio during the current influenza season (73,000 per 1 Mio inhabitants) in Germany, thereby representing a massive health challenge for the broad population.

An example for high-risk patients with viral respiratory infections - COPD patients with acute exacerbation

 

  • Especially COPD patients in advanced state are at risk for severe complication when infected with Influenza or other respiratory viruses triggering an exacerbation.
  • A meta-analysis (Zwaans et al. 2014) including 19 cross-sectional, prospective studies and case-controlled studies, comprising 1728 patients revealed, that in up to 95% of all COPD exacerbation cases viral infection played a significant role. Rhino-/enteroviruses were most prevalent followed by RSV and Influenza. Influenza virus prevalence varied significantly among studies ranging from 2.3% to 48%

 


 

Therapeutic options for an acute Influenza infection

Drugs that target viral structures directly include neuraminidase inhibitors and polymerase inhibitors

  • Oseltamivir (TamifluTM) is -despite strong resistance formation- the leading approved anti-viral drug to combat influenza infection

Markets Tamiflu

Novel derivatives of neuraminidase and polymerase inhibitors under development are tackling viral structures like TamiFluTM thus suffering from rapid resistance development as well.

 


 

Drugs with different mode-of-action

    • An alternative to the above-mentioned inhibitors is DAS181 (Fludase, NextBio Inc.), which removes the cellular receptors for the virus, the sialic acids from the cell surface. The compound is still in early clinical development and suffers from severe side effects.
    • Verdinexor (Karyopharm) is in early clinical development. It’s mode of action is the permanent blockade of nuclear export .No results have been published yet.

 

Atriva Drugs

MEK inhibitors show strong promise as first-in-class antiviral drugs that target cellular kinases transiently, providing all the advantages that are unmatched by current competing approaches.

Address

Atriva Therapeutics GmbH
Christophstr. 32, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.
Data Protection Rules I Agree